C.R. Bard introduced its Recovery IVC filter in 2003, marketing it as a retrievable temporary device. Post-market studies quickly revealed alarmingly high fracture rates — struts breaking off the filter body and traveling through the bloodstream to the heart, lungs, and other organs. Bard's internal communications, now part of the MDL discovery record, show that company engineers and executives knew about the fracture risk years before the FDA acted. Rather than disclosing the defect or issuing a recall, Bard transitioned to the G2 model — which shared the same fundamental design flaw — without notifying implanting physicians or patients.

Bard's IVC filter product line includes the Recovery, G2, G2X (also called G2 Express), Eclipse, Meridian, and Denali filters. The Recovery and G2 models carry the highest documented fracture rates and command the highest settlement values in the MDL program. If you had any of these Bard filter models, you may be eligible for compensation through the global settlement framework now administered by the MDL Plaintiffs' Steering Committee.

Becton, Dickinson and Company acquired C.R. Bard in 2017 for approximately $24 billion and assumed all IVC filter product liabilities. As a publicly traded company with significant reputational and financial exposure, BD reached a confidential global settlement framework with plaintiffs' leadership approximately in 2022 to 2023. Most remaining Bard MDL cases are now resolving under a tiered settlement grid. New cases are still being accepted into the settlement program — Contact a qualified attorney today to begin the enrollment process.